Co-Diagnostics Inc
NASDAQ:CODX
Co-Diagnostics Inc
Total Liabilities & Equity
Co-Diagnostics Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Co-Diagnostics Inc
NASDAQ:CODX
|
Total Liabilities & Equity
$44.7m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Liabilities & Equity
$43.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Liabilities & Equity
$47.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Liabilities & Equity
$86.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
Total Liabilities & Equity
$3.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Liabilities & Equity
$20.5B
|
CAGR 3-Years
16%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
Co-Diagnostics Inc
Glance View
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
See Also
What is Co-Diagnostics Inc's Total Liabilities & Equity?
Total Liabilities & Equity
44.7m
USD
Based on the financial report for Sep 30, 2025, Co-Diagnostics Inc's Total Liabilities & Equity amounts to 44.7m USD.
What is Co-Diagnostics Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-4%
Over the last year, the Total Liabilities & Equity growth was -38%. The average annual Total Liabilities & Equity growth rates for Co-Diagnostics Inc have been -33% over the past three years , -4% over the past five years .
